Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O75762
UPID:
TRPA1_HUMAN
Alternative names:
Ankyrin-like with transmembrane domains protein 1; Transformation-sensitive protein p120; Wasabi receptor
Alternative UPACC:
O75762; A6NIN6
Background:
Transient receptor potential cation channel subfamily A member 1 (TRPA1), also known as the Wasabi receptor, plays a pivotal role in detecting environmental irritants and endogenous inflammatory signals, leading to pain perception. It is activated by various compounds, including those from mustard oil, garlic, and vehicle exhaust, and shows a preference for divalent over monovalent cations. TRPA1's involvement in cold perception, oxygen sensing, and inner ear function highlights its broad physiological significance.
Therapeutic significance:
The association of TRPA1 with familial episodic pain syndrome underscores its therapeutic potential. Targeting TRPA1 could offer relief for patients suffering from this debilitating condition, emphasizing the importance of understanding its function for developing novel pain management strategies.